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Conclusion: The 5-azacitidine is a treatment modality that
can improve or stabilize the disease, allowing time for
patients to reach alloHCT, with little toxicity, and can induce
response after post-alloHCT relapses.Table 1
Study 201: Mean (N) Change from Baseline in GFR (mL/min/1.73m2) by Visit
and Dose
Visit Placebo CMX001
40 mg
QW
CMX001
100 mg
QW
CMX001
200 mg
QW
CMX001
100 mg
BIW
Week 2 -6.5 (56) -7.7 (23) -11.6 (26) -9.5 (37) -4.5 (49)
Week 4 -8.7 (46) -9.4 (19) -8.6 (25) -12.4 (31) -3.3 (44)
Week 6 -10.1 (35) -7.0 (13) -12.0 (22) -1.9 (24) 1.3 (33)
Week 8 -18.5 (36) -2.2 (12) -11.3 (19) 5.8 (18) 12.2 (31)*
Week 10 -15.4 (21) -7.3 (5) -15.6 (13) 5.7 (14) 6.1 (21)*
Post-Week 1 -13.3 (57) -5.8 (19) -2.8 (25) 8.8 (35) 7.7 (49)*
* P< 0.05 t-test versus placebo379
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted inside
cells to the active antiviral, cidofovir diphosphate. In the
preclinical toxicology program, GI AEs (diagnosed as gas-
tropathy and enteropathy; dose-related changes included
ﬂattening or loss of epithelial cells lining the lumen of the
small intestine on chronic dosing) were dose-limiting after
daily administration; however, therewere no GI AEs or gross/
microscopic gut changes when animals were dosed twice-
weekly (BIW) up to 9 months. Radiolabel studies in mice
conﬁrmed that CMX001 concentrates in the gut mucosa
more than in other tissues. In a Phase 2 dose-escalation study
(CMX001-201; ClinicalTrials.gov identiﬁer: NCT00942305)
evaluating CMX001 for CMV prophylaxis in allogeneic
hematopoietic stem cell transplant (HSCT) recipients, an
increased rate of profusewatery diarrheawas seen at 200mg
BIW and was considered dose-limiting in this population. A
program-wide safety monitoring and management plan that
included an option for dose interruption ( 2 weeks) in
subjects with  Grade 3 diarrhea was introduced. Subse-
quently, few subjects ( 10%) discontinued therapy because
of GI AEs, indicating that dose interruption is an appropriate
strategy to manage CMX001-associated GI AEs and to ach-
ieve effective CMV suppression in this population.
Methods: Serum chemistry data were evaluated for changes
in SA, a well-established marker of protein loss, to assess the
potential relationship to diarrhea. Abnormally low SA
concentrations were tabulated and the lowest value identi-
ﬁed through +1 week post treatment. A clinically meaningful
SA decrease was deﬁned as value  30 g/L (lower limit of
normal 33 g/L) and  4 g/L lower than baseline.
Results: Increased grade and/or duration of diarrhea corre-
lated with the decrease in SA concentrations over time as
shown in the Kaplan-Meier plots with data grouped by “low”
( 100mg/week) and “high” ( 200mg/week) CMX001 dose
vs. placebo. To rule out GI-GVHD (a common cause of diar-
rhea in HSCT recipients), the SA data from solid organ
transplant (SOT) patients treated with CMX001 in an
expanded access study (CMX001-350; ClinicalTrials.gov ID:
NCT01143181) were also evaluated. A similar timing of
decrease in SA concentrations was seen in these subjects
who are unlikely to have GVHD; urinalysis data also excluded
proteinuria as a cause.
Conclusions: Our clinical experience in the HSCT population
is consistent with preclinical ﬁndings. On chronic dosing,
CMX001 likely accumulates in the gut mucosa in some
patients and causes diarrhea that may be more pronounced
in individuals with other causes of diarrhea (eg, GI-GVHD).
Dose interruption gives the gut mucosa time to recover,
allowing subjects the opportunity to resume therapy.Monitoring SA changes in patients may provide an early and
objective indicator of potential drug-related GI AEs.380
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted intra-
cellularly into the active antiviral, cidofovir diphosphate.
Unlike cidofovir, CMX001 is not a substrate for the anion
organic transporter and therefore is not concentrated in the
kidney.
Methods: Study CMX001-201 was a 9-11 week randomized,
placebo-controlled, double-blind, dose-escalation study
(evaluating 40 mg weekly [QW], 100 mg QW, 200 mg QW,
200mg twice-weekly [BIW] and 100mg BIW) of CMX001 for
the prevention of CMV infection post-HCT (ClinicalTrials.gov
ID: NCT00942305). Treatment was initiated at the time of
engraftment and continued until Week 13 post-HCT. Results
presented elsewhere have shown that CMX001, at various
doses, was active andwell tolerated in the prevention of CMV
infection or disease. Renal safety was assessed throughout
the duration of therapy using serum creatinine, urinalysis
and estimated glomerular ﬁltration rate (GFR, MDRD4
formula).
Results: 230 subjects were enrolled in the study; 59
received placebo and 171 received CMX001 at various
doses. 24 subjects (41%) on placebo and 77 subjects on
CMX001 (45%) had BK viruria prior to dosing. One subject
discontinued CMX001 40 mg QW due to acute renal failure;
no other subject discontinued from the study due to renal
adverse events. Results of calculated GFR by Study Cohort
and over time are presented in Table 1 below. Overall, renal
function tended to decline in placebo recipients while renal
function appeared to improve in subjects who received
CMX001 at 200 mg per week (either QW or divided into
2 BIW doses). The renal function decline in placebo
recipients appeared to be associated by the presence of
BK virus (BKV) in the urine at the time of treatment
commencement, while the proportion of subjects with
renal dysfunction was similar between BKV positive and
negative subjects among CMX001 recipients. There was
also a decreased incidence of microscopic hematuria in
BKV infected subjects treated with CMX001 as compared
to placebo recipients (6% vs. 25%).
Conclusions: CMX001 when administered at doses of 200
mg per week is not associated with signs of nephrotoxicity
